| Literature DB >> 32223393 |
Reena M Ghosh1, Heather M Griffis2, Andrew C Glatz1,2, Jonathan J Rome1, Christopher L Smith1, Matthew J Gillespie1, Kevin K Whitehead1, Michael L O'Byrne1,2, David M Biko3, Chitra Ravishankar1, Aaron G Dewitt4, Yoav Dori1.
Abstract
Background Recent studies suggest that lymphatic congestion plays a role in development of late Fontan complications, such as protein-losing enteropathy. However, the role of the lymphatic circulation in early post-Fontan outcomes is not well defined. Methods and Results This was a retrospective, single-center study of patients undergoing first-time Fontan completion from 2012 to 2017. The primary outcome was early Fontan complication ≤6 months after surgery, a composite of death, Fontan takedown, extracorporeal membrane oxygenation, chest tube drainage >14 days, cardiac catheterization, readmission, or transplant. Complication causes were assigned to 1 of 4 groups: (1) Fontan circuit obstruction, (2) ventricular dysfunction or atrioventricular valve regurgitation, (3) persistent pleural effusions in the absence of Fontan obstruction or ventricular dysfunction, and (4) chylothorax or plastic bronchitis. T2-weighted magnetic resonance imaging sequences were used to assess for lymphatic perfusion abnormality. The cohort consisted of 238 patients. Fifty-eight (24%) developed early complications: 20 of 58 (34.5%) in group 1, 8 of 58 (14%) in group 2, 18 of 58 (31%) in group 3, and 12 of 58 (20%) in group 4. Preoperative T2 imaging was available for 126 (53%) patients. Patients with high-grade lymphatic abnormalities had 6 times greater odds of developing early complications (P=0.001). Conclusions There is substantial morbidity in the early post-Fontan period. Half of those who developed early complications had lymphatic failure or persistent effusions unrelated to structural or functional abnormalities. Preoperative T2 imaging demonstrated that patients with higher-grade lymphatic perfusion abnormalities were significantly more likely to develop early complications. This has implications for risk stratification and optimization of patients before Fontan palliation.Entities:
Keywords: Fontan procedure; cardiovascular magnetic resonance imaging; congenital heart disease; lymph; morbidity/mortality
Mesh:
Year: 2020 PMID: 32223393 PMCID: PMC7428641 DOI: 10.1161/JAHA.119.015318
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Lymphatic perfusion patterns.
A, Schematic representation. B, T2 imaging. Reprinted from Biko et al10 with permission. Copyright ©2019, the Radiological Society of North America.
Figure 2Flow diagram of patients presenting for Fontan completion.
Baseline Characteristics of Cohort
| Characteristic | All Patients (n=226) | No Complications (n=168) | Early Complications (n=58) |
| |||
|---|---|---|---|---|---|---|---|
| Sex | |||||||
| Men | 138 | (61) | 99 | (59) | 39 | (67) | 0.263 |
| Women | 88 | (39) | 69 | (41) | 19 | (33) | |
| Anatomical feature | |||||||
| HLHS | 126 | (56) | 98 | (58) | 28 | (48) | 0.184 |
| Other | 100 | (44) | 70 | (42) | 30 | (52) | |
| Systemic ventricle | |||||||
| RV | 160 | (71) | 113 | (67) | 47 | (81) | 0.047 |
| LV | 66 | (29) | 55 | (33) | 11 | (19) | |
| Systemic venous anomaly | |||||||
| No | 186 | (82) | 137 | (82) | 49 | (84) | 0.614 |
| Yes | 40 | (18) | 31 | (18) | 9 | (16) | |
| Pulmonary venous anomaly | |||||||
| No | 214 | (95) | 160 | (95) | 54 | (93) | 0.51 |
| Yes | 12 | (5) | 8 | (5) | 4 | (7) | |
| Heterotaxy | |||||||
| No | 209 | (92) | 156 | (93) | 53 | (91) | 0.774 |
| Yes | 17 | (8) | 12 | (7) | 5 | (9) | |
| Stage 3 | |||||||
| ECFF | 184 | (81) | 133 | (79) | 51 | (88) | 0.491 |
| Other | 42 | (18) | 35 | (21) | 7 | (12) | |
| Genetic anomaly | |||||||
| No | 197 | (87) | 149 | (89) | 48 | (83) | 0.244 |
| Yes | 29 | (13) | 19 | (11) | 10 | (17) | |
Data presented as number (percentage) or median (interquartile range), with P value. AVVR indicates atrioventricular valve regurgitation; CPB, cardiopulmonary bypass; ECFF, extracardiac fenestrated Fontan; HLHS, hypoplastic left heart syndrome; LV, left ventricle; MRI, magnetic resonance imaging; RV, right ventricle; SPC, systemic‐pulmonary arterial collateral; and XC, cross‐clamp time.
Significant P value.
Includes lateral tunnel fenestrated Fontans and all nonfenestrated Fontans.
AVVR quantification by MRI was only available for 173 patients (118 had no complications, 55 had early complications).
SPC quantification by MRI was only available for 194 patients (136 had no complications, 58 had early complications).
Early Complications
| Type of Complication | No. (%) of Patients (n=58) |
|---|---|
| >14 d with chest tube | 28 (48) |
| Readmissions | 33 (57) |
| Cardiac catheterizations | 40 (70) |
| Catheter‐based intervention | 27 (46) |
| ECMO | 6 (10) |
| Listed for transplant | 3 (5) |
| Fontan takedown | 3 (5) |
| Death | 2 (3) |
ECMO indicates extracorporeal membrane oxygenation.
Each complication type is counted only once.
All 3 patients were on ECMO before their Fontan takedown.
Both patients were on ECMO.
Analysis of Patients With Clinical T2 Imaging Performed
| Variable | No T2 Imaging (n=104) | T2 Imaging (n=122) |
| ||
|---|---|---|---|---|---|
| Sex | |||||
| Men | 68 | (65) | 70 | (57) | 0.219 |
| Women | 36 | (35) | 52 | (43) | |
| Systemic ventricle | |||||
| RV | 65 | (63) | 95 | (78) | 0.011 |
| LV | 39 | (38) | 27 | (22) | |
| Systemic venous anomaly | |||||
| No | 86 | (83) | 100 | (82) | 0.887 |
| Yes | 18 | (17) | 22 | (18) | |
| Pulmonary venous anomaly | |||||
| No | 99 | (95) | 115 | (94) | 1 |
| Yes | 5 | (5) | 7 | (6) | |
| Heterotaxy | |||||
| No | 98 | (94) | 111 | (91) | 0.451 |
| Yes | 6 | (6) | 11 | (9) | |
| Heterotaxy type | |||||
| Polysplenia | 2 | (33) | 1 | (9) | 0.515 |
| Asplenia | 4 | (67) | 10 | (91) | |
| Stage 3 | |||||
| ECFF | 83 | (80) | 101 | (83) | 0.609 |
| Other | 21 | (20) | 21 | (17) | |
| Genetic anomaly | |||||
| No | 91 | (88) | 106 | (87) | 0.89 |
| Yes | 13 | (13) | 16 | (13) | |
| CPB time, min | 67 | (59–79) | 65.6 | (60–77) | 0.521 |
| XC, min | 26 | (21–34) | 26.5 | (22–32) | 0.910 |
| % AVVR by MRI | 5 | (1–8.5) | 7 | (1–11) | 0.075 |
| % SPC by MRI | |||||
| <35% | 52 | (76) | 82 | (69) | 0.5 |
| 35%–50% | 14 | (21) | 29 | (25) | |
| >50% | 2 | (3) | 7 | (6) | |
Data presented as number (percentage) or median (interquartile range), with P value. AVVR indicates atrioventricular valve regurgitation; CPB, cardiopulmonary bypass; ECFF, extracardiac fenestrated Fontan; LV, left ventricle; MRI, magnetic resonance imaging; RV, right ventricle; SPC, systemic‐pulmonary arterial collateral; and XC, cross‐clamp time.
Significant P value.
Includes lateral tunnel fenestrated Fontans and all nonfenestrated Fontans.
AVVR quantification by MRI was only available for 173 patients (60 had no T2 imaging, 113 had T2 imaging).
SPC quantification by MRI was only available for 194 patients (72 had no T2 imaging, 122 had T2 imaging).
Lymphatic Perfusion Outcomes and Early Complications
| Perfusion Pattern | Total (n=122) | Early Complications (n=37) | No Complications (n=85) |
|
|---|---|---|---|---|
| Type 1 | 39 | 6 | 33 | 0.001 |
| Type 2 | 41 | 9 | 32 | |
| Type 3 | 35 | 15 | 20 | |
| Type 4 | 7 | 7 | 0 |
Odds of Developing Early Complications Based on Lymphatic Perfusion Pattern
| Lymphatic Perfusion Pattern | No. (%) of Patients (N=122) | Unadjusted OR (95% CI) |
| Adjusted OR (95% CI) |
|
|---|---|---|---|---|---|
| Type 1 | 39 (32) | Reference | ··· | ··· | ··· |
| Type 2 | 41 (34) | 1.55 (0.49–4.85) | 0.454 | 1.56 (0.48–5.00) | 0.458 |
| Type 3+4 | 42 (35) | 6.05 (2.10–17.46) | 0.001 | 6.28 (2.13–18.5) | 0.001 |
OR indicates odds ratio.
Total number of patients with T2 imaging available for an analysis of lymphatic perfusion pattern.
Results hold after adjusting for cardiopulmonary bypass (CPB) time and ventricular morphological characteristics (left ventricle vs right ventricle [RV], with RV as reference group: OR, 0.46 [95% CI, 0.15–1.39] [P=0.168]; CBP time: OR, 1.02 [95% CI, 0.99–1.06] [P=0.213]).
Results for type 3 and type 4 hold separately.
Significant P value.